Shares of XBiotech Inc. (NASDAQ:XBIT - Get Free Report) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $3.00 and traded as high as $3.55. XBiotech shares last traded at $3.39, with a volume of 29,929 shares traded.
XBiotech Price Performance
The stock's 50 day moving average is $3.01 and its two-hundred day moving average is $3.03. The stock has a market capitalization of $96.35 million, a PE ratio of -3.43 and a beta of 0.85.
XBiotech (NASDAQ:XBIT - Get Free Report) last released its earnings results on Wednesday, August 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter.
Institutional Trading of XBiotech
A number of large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its stake in shares of XBiotech by 27.1% during the second quarter. BNP Paribas Financial Markets now owns 20,729 shares of the biopharmaceutical company's stock worth $62,000 after buying an additional 4,416 shares during the period. Bank of America Corp DE increased its stake in XBiotech by 41.5% in the second quarter. Bank of America Corp DE now owns 18,208 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 5,344 shares during the last quarter. Jane Street Group LLC purchased a new position in XBiotech in the second quarter valued at approximately $75,000. RBF Capital LLC purchased a new position in XBiotech in the second quarter valued at approximately $594,000. Finally, Qube Research & Technologies Ltd purchased a new position in XBiotech in the second quarter valued at approximately $96,000. 55.70% of the stock is currently owned by hedge funds and other institutional investors.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Featured Stories
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
